Mr. Cohen had been serving as MediWound’s CEO since November 2006.
Prior to joining MediWound, Mr. Cohen held several management positions at Teva Pharmaceutical Industries Ltd. as Director of Strategic Business Planning & New Ventures, Projects Manager for the Global Products Division and Team Leader at Teva’s Corporate Industrial engineering department. During this period, he led various business transactions and alliances with start-up companies and academic institutions, was the Project Manager of the launch of Copaxone®, Teva’s flagship innovative product, in numerous countries as well as for the development of various medical devices.
Mr. Cohen holds a cum laude B.Sc. in Industrial Engineering & Management from the Technion -Israel’s Institute of Technology and a cum laude MBA from Tel-Aviv University.
Mr. Malka joined MediWound as CFO in April 2007.Prior to joining MediWound, he served as a partner at Varinace Economic Consulting Ltd., a full-service consulting firm and as a senior manager at Kesselman Corporate Finance, a division of PricewaterhouseCoopers Global Network (PwC). Mr. Malka’s has vast experience in business and economic consulting, including valuations, SEC filing, feasibility studies and financial&strategic planning.
Mr. Malka holds a B.Sc. in Business Administration from the Business Management College, Israel and an MBA from Bar Ilan University, Israel.
Prof. Rosenberg was one of the founders of MediWound and has been serving as MediWound Chief Medical Officer since its inception.
Prof. Rosenberg headed the Department of Plastic Surgery at Soroka University Medical Center in Beer Sheva, heads the unit for Cleft Lip Palate & Craniofacial deformities at Meir Medical Center, Kfar Saba, is a Professor of Medicine at the Ben-Gurion University Medical School in Beer Sheva and the International Society for Burn Injuries-Chairman of Disaster committee. His years of pioneering work with the product and his expertise and extensive personal ties with key opinion leaders in the field of burns and wound care form the clinical basis of MediWound’s development program. Prof. Rosenberg has given more than 100 presentations relating to NexoBrid™ at international conferences, published numerous peer-reviewed papersand led several wound care products from conception to market.
Prior to joining MediWound, Dr. Klinger was Vice President of Research and Development at Proteologics Ltd since July 2011, where she was responsible for discovery projects in the ubiquitin system, conducted in collaboration with GlaxoSmithKline plc and Teva Pharmaceutical Industries Ltd. Prior to this, Dr. Klinger served for 17 years in numerous leadership positions at Teva’s global innovative R&D division and served as Teva’s Board representative at various biotechnology companies. Dr. Klinger was a key member of the Copaxone® development team. As a project leader she led the chemistry, manufacture and control, preclinical, clinical and post-marketing R&D activities of various innovative treatments for multiple sclerosis (MS), autoimmune and neurological diseases. From 2006 to 2011, as a Senior Director at Teva, Dr. Klinger was a member of Teva’s global innovative R&D management team. From 2006 to 2008, she served as the Head of MS and Autoimmune Diseases at Teva, and led the Life Cycle Management (LCM).
Mr. Henke has been serving as Chief Commercial Officer for the European organization since October 2014 and is acting as the Managing Director of MediWound Germany since July 2013.
Prior to joining MediWound, Mr. Henke held several senior management positions at Teva Pharmaceutical Industries Ltd. as General Manager in Spain and as Director of Marketing and Sales in Germany. During this period, he established various sales and marketing organizations and has successfully launched and marketed pharmaceutical products. Amongst them, Copaxone®, Teva’s flagship innovative product, which became the number one prescribed MS treatment in Germany under his leadership. In his long career, Mr. Henke has worked in many additional commercial roles in Serono, Sanofi and the Merck Group.
Mr. Henke holds a cum laude B.Sc. in European Management from the ESB Business School at Reutlingen University and a “Graduado Superior” in International Business Administration- E-4 from Comillas Pontifical University ICAI – ICADE in Madrid.
Mr. Meyer joined MediWound as General Counsel and Corporate Secretary in December 2013. Prior to joining MediWound he served as the corporate secretary of Clal Biotechnology Industries Ltd., as the General Counsel and Corporate Secretary of D-Pharm Ltd, as a legal counsel of Clal Industries Ltd. and as an associate at Shibolet & Co. Advocates. Mr. Meyer has vast experience in corporate law, biotechnology field and public companies.
Mr. Meyer holds an LL.B. degree from Haifa University, Israel.
Mr. Kon has been serving as Head of Production of MediWound since its inception.
Mr. Kon has over 20 years of experience in the biotech industry. Prior to founding MediWound he served as head of production of Omrix pharmaceuticals Inc.
Mr. Kon holds a M.Sc. in Biotechnology from St. Petersburg pharmaceutical institute.
Dr. Asculai serves as MedWound’s Vice President, R&D since July 2007. Prior to joining Mediwound, Dr. Asculai was the Senior Director of the Pharmaceutical R&D at Perrigo Israel Pharmaceuticals. In this position, he managed all pharmaceutical development activities from initiation to submission. Dr. Asculai led a considerable senior scientific and technical staff in the process of development of generic and innovative products. During his service at Perrigo, the pharmaceutical R&D specialized mainly in topical and dermatological products and became one of the world’s leading R&D groups in this field. Prior to his last position, Dr. Asculai served for nine years, in various management positions in Perrigo in Pharmaceutical R&D.
Dr. Asculai holds B.Sc., M.Sc. (Summa cum Laude), Ph.D in Medical Sciences, and MBA (hons.) degrees, all from the Ben-Gurion University.
Ms. Nestor serves as MediWound’s Director of Regulatory Affairs since January 2008.
Ms. Nestor has over 10 years of experience in the field of international regulatory affairs. Prior to joining MediWound, she was responsible for the planning and coordinating of key regulatory activities in the pharmaceutical industry while working for CollgardBiopahrmaceuticals Ltd as a Regulatory Affairs Manager and for Teva Pharmaceutical Industries Ltd as a Regulatory Affairs Product Manager.
Ms. Nestor holds a B.Sc. in Pharmacy from the Hebrew University of Jerusalemand a M.Sc., with distinction, in Human Genetics from the Faculty of Medicine, Tel Aviv University, Israel.
Mr. Leuw has been serving as MediWound’s Director of Quality Assurance & Control since November 2007. Mr. Leuw has over 20 years of experience in the field of quality in the pharmaceutical and biotechnology industry. Prior to joining MediWound, he served for 3 years as Director of Quality Assurance & Control at Prochon Biotech company and for 11 years at Teva Pharmaceutical Industries Ltd where he served in several positions in Quality Assurance.
Mr. Leuw holds a B.Sc. in Chemistry from Ben Gurion University, Israel
Ms. David serves as MediWound’s Director of Clinical Affairs since March 2013.
Ms. David joined the Clinical department at MediWound 8 years ago and since then was responsible for managing global phase 2 and phase 3 studies.
Ms. David holds a B.Sc. and M.Sc. with distinction from the Faculty of Biotechnology and Food Eengineering from the Technion -Israel Institute of Technology.
Mrs. Solomon joined MediWound in November 2006.Prior to joining MediWound, she served in several financial positions in private companies. Mrs. Solomon has vast experience in accounting, budgeting and financial planning & control.
Mrs. Solomon holds a B.Sc. in Business Administration from the Business Management College, Israel and a MBA from NYU Polytechnic School of Engineering, New-York.
Dr. Shoham joined MediWound in January 2013.He is a practicing board-certified Plastic and Reconstructive Surgeon with a special interest in burns, wounds and reconstructions.
Dr. Shoham holds an M.D. degree from the Ben-Gurion University of the Negev and is a member of the Israeli Society of Plastic and Aesthetic Surgery, the American Burn Association, the European Burn Association and the Israeli Burn Association.
MediWound’s innovative drug, NexoBrid™, was approved in December 2012 by EMA via a centralized procedure and was granted orphan indication for removal of eschar in adults with deep partial- and full-thickness thermal burns (also known as debridement)